Can CDTX sustain its Q1 2024 earnings growth?

**CDTX's ability to sustain its Q1 2024 earnings growth is uncertain and depends on several factors**:

1. **Recent Performance and Analyst Estimates**: Cidara Therapeutics (CDTX) has experienced a significant decline in net income, with a year-over-year growth rate of -1527.98% as of December 31, 2024, compared to an earlier period. Additionally, analysts have decreased their EPS estimates for Q1 2024, indicating a negative outlook on the company's earnings in the immediate term.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|CDTX|CDTX.O|Cidara Therapeutics|2023 Q2|-3.849378763625276|-1.3624E7|186|
|CDTX|CDTX.O|Cidara Therapeutics|2023 Q3|-160.80251034851113|-9107000|186|
|CDTX|CDTX.O|Cidara Therapeutics|2023 Q4|81.2784057802121|-3213000|186|
|CDTX|CDTX.O|Cidara Therapeutics|2024 Q1|-442.71490209093923|-1.0326E7|186|

2. **Investor Sentiment and Price Target**: The stock's price target is $46, with an "Outperform" rating from Citizens JMP, suggesting a potential upside. However, the company's negative P/E ratio of -0.48 reflects investor skepticism about future earnings.
3. **Company's Strategic Moves**: Cidara Therapeutics has expanded its Scientific Advisory Board, which could potentially positively influence the company's future prospects.
4. **Global Economic Conditions**: The company's operations could be adversely affected by unfavorable global economic conditions, such as active conflicts in the Middle East and the conflict between Russia and Ukraine.
5. **Market Perception and Fundraising**: The company's ability to raise capital and continue operations may be impaired if it fails to achieve or maintain profitability.

In conclusion, while there are some positive strategic moves and potential for growth, the current financial estimates and market sentiment suggest that sustaining earnings growth in Q1 2024 may be challenging for CDTX. The company's ability to turn around its earnings trajectory will depend on successful execution of its strategic plans, favorable global economic conditions, and maintaining investor confidence.